Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.

Kontopoulou, Konstantina; Ainatzoglou, Alexandra; Nakas, Christos T.; Ifantidou, Athina; Goudi, Georgia; Antoniadou, Eleni; Adamopoulos, Vasilios; Papadopoulos, Nikitas; Papazisis, Georgios (2021). Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive. Vaccine, 39(36), pp. 5078-5081. Elsevier 10.1016/j.vaccine.2021.07.065

Text Second_Dose.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (375kB) | Request a copy

This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20-67. After the first dose, titers varied upon age and history of infection, being lower in the 50+ age group and significantly higher among the seropositive. After the second dose, immunogenicity was significantly boosted in the age 50+ and SARS-CoV-2-naïve individuals, indicating the effectuality of its timely administration, yet questioning its value among the seropositive.

Interest & Impact

Downloads

1 since deposited on 16 Nov 2021
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item